Our previous studies suggested MKK3 as a general molecular player required to sustain cell proliferation and survival not only in mutp53-bearing but also in p53-null cancer lines.9 Here, we wanted to evaluate whether MKK3 played a role also in wild-type (wt) p53-bearing cells and its impact on both mup53 and wtp53 tumor cell response to anticancer drugs, investigating the molecular mechanisms involved in the biological outcomes upon MKK3 depletion. Here, MAP2K3 is linked to cancer.